Premium
Poly(methyl malate) Nanoparticles: Formation, Degradation, and Encapsulation of Anticancer Drugs
Author(s) -
LanzLandázuri Alberto,
GarcíaAlvarez Montserrat,
PortillaArias José,
Martínez de Ilarduya Antxon,
Patil Rameshwar,
Holler Eggehard,
Ljubimova Julia Y.,
MuñozGuerra Sebastián
Publication year - 2011
Publication title -
macromolecular bioscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 105
eISSN - 1616-5195
pISSN - 1616-5187
DOI - 10.1002/mabi.201100107
Subject(s) - chemistry , hydrolysis , methanol , in vitro , nanoparticle , doxorubicin , incubation , viability assay , malic acid , degradation (telecommunications) , nuclear chemistry , biochemistry , biophysics , organic chemistry , chemical engineering , medicine , telecommunications , surgery , chemotherapy , computer science , citric acid , engineering , biology
PMLA nanoparticles with diameters of 150–250 nm are prepared, and their hydrolytic degradation is studied under physiological conditions. Degradation occurs by hydrolysis of the side chain methyl ester followed by cleavage of the main‐chain ester group with methanol and L ‐malic acid as the final degradation products. No alteration of the cell viability is found after 1 h of incubation, but toxicity increases significantly after 3 d, probably due to the noxious effect of the released methanol. Anticancer drugs temozolomide and doxorubicin are encapsulated in the NPs with 20–40% efficiency, and their release is monitored using in vitro essays. Temozolomide is fully liberated within several hours, whereas doxorubicin is steadily released from the particles over a period of 1 month.